₹509.65
+2.29%NSE close, 16 Nov 2026
+9.91%
Thyrocare Technologies is a small cap company in the Healthcare sector, listed on NSE under the symbol THYROCARE. At ₹509.65 a share, the market values the whole company at ₹8,112 crore.
In FY26, it reported sales of ₹829 crore and a net profit of ₹163 crore, an operating margin of 31.6%. Over the last three years, sales grew 16.3% a year and net profit grew 36.3% a year.
The market values the company at 56.3 times its profit over the last twelve months and 14.66 times its book value; its return on equity is 26.1% and it has almost no borrowings.
Promoters hold 51.02% of the shares. Foreign institutions hold 9.37%, and domestic institutions, mutual funds among them, 25.92%.
Over the past year the share price has risen 15.5%, and it is 23.0% below its 52-week high.
Companies of a similar size in the same sector include Yatharth Hospital & Trauma Care Services, Blue Jet Healthcare, Procter & Gamble Health and Strides Pharma Science.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Thyrocare Technologies | ₹509.65 | ₹8,112 cr | 56.3 | 26.1% | +25.10% | +15.46% |
| Yatharth Hospital & Trauma Care Services | ₹1,069.05 | ₹10,301 cr | 54.9 | 10.0% | +54.40% | +34.65% |
| Blue Jet Healthcare | ₹512.95 | ₹9,709 cr | 34.0 | 12.4% | +127.10% | −8.67% |
| Procter & Gamble Health | ₹5,595.50 | ₹9,288 cr | 24.5 | 57.7% | +17.70% | −6.69% |
| Strides Pharma Science | ₹986.10 | ₹9,089 cr | 14.7 |
Allotment of 194289 Equity Shares pursuant to the Thyrocare Employee Stock Option Scheme.
Resignation of Dr. Preet Kaur as Chief Scientific Officer of the company w.e.f. November 06, 2026.
Transcript
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 135 | 154 | 157 | 177 | 166 | 187 | 193 | 217 | 196 | 224 | 240 | 271 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 103 | 120 | 114 | 129 | 124 | 129 | 135 | 145 | 138 | 149 | 163 | 182 |
| Operating profit | 31.6 | 33.8 | 42.6 | 48.3 | 41.7 | 57.7 | 57.8 | 71.4 | 57.8 | 75.1 | 77.3 | 89.3 |
| Operating margin | 23.4% | 21.9% | 27.2% | 27.2% | 25.2% | 30.8% | 29.9% | 33.0% | 29.6% | 33.5% | 32.2% | 33.0% |
| Other income | 2.7 | 3.5 | 3.6 | 2.6 | 4.0 | 4.6 | 4.7 | 3.1 | 5.0 | 4.3 | 4.2 | 3.6 |
| Interest | 1.1 | 1.1 | 1.0 | 0.8 | 0.6 | 0.7 | 0.8 | 0.6 | −0.1 | 1.5 | 1.4 | 1.6 |
| Depreciation | 13.5 | 13.1 | 11.4 | 13.1 | 17.1 | 13.8 | 11.4 | 11.5 | 21.6 | 14.0 | 12.5 | 13.5 |
| Profit before tax | 19.8 | 22.9 | 33.9 | 37.1 | 28.1 | 47.8 | 50.2 | 62.3 | 35.1 | 63.9 | 67.6 | 32.9 |
| Tax | 5.2 | 5.7 | 9.6 | −10.4 | 9.0 | 25.6 | 12.2 | 14.8 | 7.3 | 15.7 | 17.0 | 18.4 |
| Net profit | 15.4 | 17.8 | 24.2 | 26.7 | 19.1 | 21.7 | 38.9 | 48.0 | 29.0 | 47.1 | 52.2 | 15.9 |
| EPS (₹) | 2.78 | 3.54 | 4.52 | 4.99 | 3.58 | 4.17 | 7.35 | 9.05 | 1.82 | 2.99 | 3.23 | 0.96 |
₹ crore, financial years to March.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 403 | 433 | 495 | 589 | 527 | 572 | 687 | 829 |
| Expenses | 249 | 261 | 323 | 354 | 407 | 434 | 497 | 567 |
| Operating profit | 154 | 173 | 171 | 235 | 120 | 137 | 190 | 262 |
| Operating margin | 38.3% | 39.8% | 34.6% | 39.9% | 22.8% | 24.0% | 27.7% | 31.6% |
| Other income | 10.0 | 7.7 | 12.4 | 29.3 | 8.4 | 9.4 | 14.8 | 17.0 |
| Interest | 0.6 | 1.9 | 0.9 | 2.4 | 2.4 | 4.2 | 3.1 | 2.8 |
| Depreciation | 26.2 | 31.9 | 30.3 | 33.9 | 38.7 | 47.0 | 55.3 | 58.6 |
| Profit before tax | 137 | 140 | 153 | 228 | 87.9 | 95.4 | 147 | 211 |
| Tax | 52.9 | 52.0 | 39.3 | 51.6 | 24.2 | 26.5 | 54.7 | 50.0 |
| Net profit | 85.1 | 88.4 | 113 | 176 | 64.5 | 70.7 | 91.5 | 163 |
| EPS (₹) | 15.95 | 16.74 | 21.41 | 33.30 | 12.16 | 13.42 | 17.13 | 10.27 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 267 | 191 | 213 | 133 |
| From investing | −120 | −52.5 | −23.0 | −30.4 |
| From financing | −147 | −130 | −170 | −119 |
| Spent on fixed assets | −37.8 | −44.9 | −20.9 | −33.2 |
| Free cash flow | 229 | 146 | 192 | 99.5 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net margin | 21.1% | 20.4% | 22.9% | 29.9% | 12.2% | 12.4% | 13.3% | 19.7% |
| Operating margin | 38.3% | 39.8% | 34.6% | 39.9% | 22.8% | 24.0% | 27.7% | 31.6% |
| Return on equity | – | – | – | – | 12.1% | 13.4% | 16.7% | 27.8% |
| Return on capital employed | – | – | – | – | 16.9% | 18.2% | 27.4% | 36.6% |
| Return on assets | – | – | – | – | 10.2% | 11.0% | 13.2% | 21.8% |
| Debt to equity | – | – | – | – | 0.00 | 0.04 | 0.00 | 0.00 |
| Interest coverage | 226.20 | 76.60 | 176.30 | 97.20 | 38.40 | 23.70 | 49.20 | 76.50 |
| Debt to assets | – | – | – | – | 0.00 | 0.03 | 0.00 | 0.00 |
| Current ratio | – | – | – | – | 3.54 | 3.08 | 2.77 | 3.39 |
| Quick ratio | – | – | – | – | 3.18 | 2.55 | 2.39 | 2.95 |
| Cash ratio | – | – | – | – | 0.23 | 0.10 | 0.15 | 0.35 |
| Asset turnover | – | – | – | – | 0.83 | 0.89 | 0.99 | 1.11 |
| Fixed asset turnover | – | – | – | – | 3.35 | 3.40 | 4.62 | 4.03 |
| Inventory turnover | – | – | – | – | – | 3.50 | 4.10 | 4.50 |
| Receivables turnover | – | – | – | – | 6.20 | 13.20 | 9.40 | 11.20 |
| Gross margin | – | – | – | – | – | 70.9% | 72.2% | 73.5% |
| Cash from operations to profit | – | – | – | 152.0% | – | – | 209.0% | 131.0% |
| Effective tax rate | 38.5% | 37.2% | 25.8% | 22.6% | 27.6% | 27.8% | 37.2% | 23.7% |
| 18.1% |
| +17.10% |
| +2.78% |
| Aarti Pharmalabs | ₹986.75 | ₹8,948 cr | 35.4 | 11.2% | +45.90% | +16.93% |
|---|
| Healthcare Global Enterprises | ₹568.20 | ₹8,483 cr | 750.7 | 0.8% | +13.10% | −24.77% |
|---|
| Suven Life Sciences | ₹268.90 | ₹7,598 cr | n/a | -84.2% | +30.40% | +39.45% |
|---|
| Nephrocare Health Services | ₹642.00 | ₹6,456 cr | 50.4 | 10.8% | n/a | n/a |
|---|
Execution of Share Purchase Agreement in relation to the sale of the Company s entire shareholding in Nueclear Healthcare Limited, a wholly owned subsidiary of the Company.
A copy of Scrutinizers report of Postal Ballot and Voting results.
Link of Recording
Press Release on Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026
Outcome of board meeting held on October 29, 2026, inter-alia considered and approved the un-audited financial results for the quarter and half year ended September 30, 2026.
Schedule of meet
Notice of Postal Ballot
Grant of Options under Thyrocare Employee Stock Option Scheme.
Has informed about the sale of the entire shareholding held by the Company in Nueclear Healthcare Limited (a material wholly owned subsidiary), subject to the approval of the shareholders of the Company.
Please find attached intimation regarding Acquisition of Compulsorily Convertible Preference Shares of Trovera Healthcare Private Limited as part-consideration for the sale of Nueclear Healthcare Limited (a material wholly owned subsidiary).